Restricted IVF Insurance Coverage Doubles Likelihood of PGT-A Use

When patients face a hard ceiling on their in vitro fertilization coverage, the math changes instantly. According to findings presented at the American Society For Reproductive Medicine (ASRM) 2026, women with limited insurance benefits for fertility treatments are more likely to use preimplantation genetic testing for aneuploidy on their embryos compared to those with comprehensive plans.

How Limited Insurance Coverage Drives PGT-A Utilization

The study, discussed by researchers at an academic center in Chicago, examined records from 208 women enrolled in the PROMISE cohort study, a prospective investigation tracking patients undergoing their first cycle of IVF. Researchers categorized the participants into three distinct financial access groups following a standardized review by financial counselors: those with no insurance coverage, those with restricted coverage involving lifetime cycle or financial caps, and those with comprehensive coverage offering annual or unlimited cycle access.

Among the cohort, 23 women had no coverage, 104 faced restricted benefits, and 81 enjoyed comprehensive plans. When investigators analyzed the data, a stark pattern emerged. While biological factors like age and ovarian reserve ought to dictate whether a patient utilizes preimplantation genetic testing for aneuploidy—commonly known as PGT-A—financial constraints appeared to override clinical indicators. Study co-author Ecem Esencan, MD, a reproductive endocrinology and infertility fellow at Northwestern University, noted that patients facing finite coverage limits seemed driven to “make each cycle count.”

When patients know that their covered cycles are finite, they appear twice more likely to use PGT-A, and this was independent of their age and ovarian reserve—which are the actual biological factors that should drive the decision of using PGT-A or not. — Ecem Esencan, MD, Northwestern University

In a subset of 168 women with complete data on PGT-A utilization, 72% of those with restricted coverage pursued the genetic screening. That figure dropped to 57% among patients with comprehensive coverage and 52% for those with no coverage at all. After adjusting for age, anti-Müllerian hormone levels, and body mass index in a multivariable analysis limited to insured patients, restricted coverage remained independently linked to an increased likelihood of opting for the test, yielding an odds ratio of 2.10.

The Downstream Financial Impact on Fertility Patients

This dynamic exposes a quiet paradox in modern reproductive healthcare. Policies designed to contain costs by capping insurance benefits may inadvertently shift heavier expenses onto the patients themselves. PGT-A is not usually covered by insurance, meaning that individuals scrambling to maximize restricted cycles end up absorbing out-of-pocket fees for the supplementary testing.

Session co-moderator Alexis Hood, MD, a reproductive endocrinology and infertility fellow at Johns Hopkins Medicine in Baltimore, pointed out the broader economic implications during the ASRM discussion. If insurers maintain rigid restrictions on cycle caps, patients frequently shoulder increased costs elsewhere in their treatment path. Primary care doctors most likely will come in contact with a patient with infertility challenges, making accessible and comprehensive insurance coverage a critical component of overall patient health.

As policymakers, payers, and clinical teams digest these findings, the core question remains whether restructuring insurance caps could alleviate unnecessary financial pressure on families already coping with the high stakes of fertility care. For now, patients navigating restricted plans continue to balance the finite nature of their benefits against the heavy price of certainty.